Puberty Blockers and Cross-Sex Hormones: Documented Harms and the Collapse of the "Fully Reversible" Claim

The prescription of puberty-blocking drugs to gender-dysphoric children rests on a foundation of claims that have been progressively undermined by evidence, regulatory reviews, and the testimony of trans-identified adults and detransitioners.

GnRH agonists (gonadotropin-releasing hormone agonists) — marketed as Lupron (leuprolide) and other brand names — work by suppressing the pituitary gland's production of sex hormones (oestrogen and testosterone). They were originally developed and approved for treatment of precocious puberty (puberty starting abnormally early) and for prostate cancer in adults.

From approximately 2010 onward, their use was extended to gender-dysphoric children as a way of 'pausing' puberty — delaying the development of secondary sex characteristics — while the child decided whether to transition. The clinical framing was that the treatment was 'fully reversible': the child stops the blockers, puberty resumes, no permanent harm done.

This claim of full reversibility is not supported by available evidence and has now been formally contested by multiple national health bodies.

The Cass Review is the largest independent investigation of gender medicine for children conducted in any country. It was commissioned by NHS England in 2020 and led by Dr Hilary Cass, a former President of the Royal College of Paediatrics and Child Health. The final report was published in April 2024.

Key findings:

• The evidence base for puberty blockers in gender dysphoria is 'remarkably weak.' The original Dutch Protocol studies — on which the entire field was built — involved approximately 70 highly selected patients with no psychiatric comorbidities, followed for limited time periods. Generalizing from this tiny, unrepresentative sample to the population of children now presenting at gender clinics was not justified.
• Virtually all children who begin puberty blockers proceed to cross-sex hormones — approximately 98% in published data. This is the opposite of what 'pause to consider' implies. Either the blockers are preventing the natural desistance that occurs in a majority of gender-dysphoric children, or they are selecting for children who were always going to persist. Either way, 'pause button' is a misleading description.
• NICE (the UK's National Institute for Health and Care Excellence) conducted a systematic review of the evidence for puberty blockers and found it of 'very low certainty.' NICE declined to recommend them as a treatment outside of research settings.
• The Cass Review recommended that puberty blockers should not be routinely prescribed to gender-dysphoric minors outside of formal research protocols. NHS England stopped prescribing them to under-18s in April 2024.

Bone density: Peak bone density is established during puberty. Suppressing puberty with blockers prevents this development. Studies show children on GnRH agonists have lower bone density than peers. Cross-sex hormones partially compensate for this in trans-identified males (estrogen supports bone density) but not fully in trans-identified females (testosterone supports bone density in males; removing that signal in adolescent females causes lasting deficit). Long-term fracture risk is elevated.

Sexual function and the orgasm question: At the 2022 Duke Medicine conference on gender medicine, Marci Bowers — a leading trans surgeon and himself a trans-identified person — stated publicly that children who begin puberty blockers at Tanner Stage 2 (early puberty, roughly age 9–11) 'have never experienced orgasm' and will never develop the capacity to do so. Puberty is when genital sensitivity and sexual response are established neurologically. Blocking puberty before this development occurs means those neural pathways are never laid down. This is not reversible.

Fertility: Children who progress from puberty blockers to cross-sex hormones before their gametes mature are permanently sterile. A male-born child who begins blockers before producing mature sperm and then begins estrogen will have no viable sperm. A female-born child who begins blockers before egg development completes and then begins testosterone will have no viable eggs.

Cognitive effects: Emerging evidence, including a documented case published by Dr P (@Psychgirl211) showing significant IQ drops (verbal, working memory, global IQ, perceptual reasoning, processing speed) in a child over approximately 2.5 years on puberty blockers, suggests potential cognitive effects. This is not proven by a single case; but given that sex hormones are known to influence brain maturation during adolescence, the concern is scientifically plausible and warrants investigation that has not been conducted.

The cross-sex hormone pathway: Children who proceed from blockers to cross-sex hormones are taking experimental drugs at doses and for purposes for which they were never approved. Estrogen in biological males causes: breast development (irreversible without surgery), redistribution of fat tissue, reduction in testicular function. Testosterone in biological females causes: clitoral enlargement (often described as irreversible), vocal cord changes (voice deepening, irreversible), menstrual disruption, potential cardiovascular effects, and at high doses over long periods, increased risk of polycythemia.

Several countries that were early adopters of pediatric gender medicine have since restricted or stopped the practice:

• Sweden (Karolinska Hospital, 2021): Karolinska was the world's leading institution for trans medicine. It stopped prescribing puberty blockers and cross-sex hormones to gender-dysphoric minors except in exceptional circumstances, citing the weak evidence base.
• Finland (2020): Finnish health authorities conducted an independent review and concluded that medical transition for gender-dysphoric minors should be 'the last resort,' available only to those with severe, long-standing, and treatment-resistant dysphoria.
• Denmark (2024): Restricted prescription of blockers and hormones to minors.
• Norway (2023): Restricted access; directed that treatment should occur only within national research protocols.
• UK NHS (2024): Stopped prescribing puberty blockers to minors outside research protocols following the Cass Review.
• United States: Several states have banned or restricted gender-transition medicine for minors. The debate is ongoing and contested.